Novacyt S.A. Launch of respiratory test panel (2644X)
27 August 2020 - 4:00PM
UK Regulatory
TIDMNCYT
RNS Number : 2644X
Novacyt S.A.
27 August 2020
Novacyt S.A.
("Novacyt", the "Company" or the "Group")
Launch of respiratory test panel
New test differentiates COVID-19 from common winter diseases
Paris, France and Camberley, UK - 27 August 2020 - Novacyt (
EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in
clinical diagnostics, announces the launch of its CE-Mark approved
polymerase chain reaction (PCR) respiratory test panel,
Winterplex(TM).
On 27 July 2020, Novacyt announced the development of a
respiratory test panel, which includes its high-performance
COVID-19 PCR test. The Winterplex(TM) test panel includes two gene
targets specific to COVID-19, as well as gene targets for influenza
A&B and respiratory syncytial virus (RSV). Clinical trial data
demonstrated 100% specificity and between 96% and 100% sensitivity
across the panel.
There remains a challenge for healthcare providers in
differentiating COVID-19 from other respiratory diseases,
particularly during a seasonal flu outbreak, due to patients
presenting with similar symptoms. This is driving the requirement
for the development of respiratory test panels that are able to
diagnose and distinguish the difference between types of flu and
COVID-19.
The test panel is designed to be used on any open PCR platform,
including the Company's rapid, portable q32 instrument. The Company
is using its existing manufacturing capacity to produce the test
panel and believes it can meet the expected global demand for the
product. The test panel is expected to drive significant
incremental revenue for the Company.
Graham Mullis, Group CEO of Novacyt, commented:
" Novacyt has established itself as a pioneer in COVID-19
diagnostics through the rapid development and success of its
COVID-19 PCR test and the launch of Winterplex(TM) is another
example of this innovative approach . We believe Winterplex(TM) is
one of the world's first approved respiratory test panels that can
differentiate between COVID-19 and other common respiratory
diseases. The test panel is a key addition to our COVID-19 product
portfolio to support healthcare providers as we approach flu season
in the Northern hemisphere."
T his announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
- End -
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and
Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
FTI Consulting (International)
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
victoria.fostermitchell@fticonsulting.com /
mary.whittow@fticonsulting.com
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 47
arnaud.decheffontaines@fticonsulting.com
About Novacyt Group
The Novacyt Group is an international diagnostics business
generating an increasing portfolio of in vitro and molecular
diagnostic tests. Its core strengths lie in diagnostics product
development, commercialisation, contract design and manufacturing.
The Company's lead business units comprise of Primerdesign and
Lab21 Products, supplying an extensive range of high-quality assays
and reagents worldwide. The Group directly serves microbiology,
haematology and serology markets as do its global partners, which
include major corporates.
For more information please refer to the website:
www.novacyt.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFVLTSIRFII
(END) Dow Jones Newswires
August 27, 2020 02:00 ET (06:00 GMT)
Novacyt (LSE:NCYT)
Historical Stock Chart
From Apr 2024 to May 2024
Novacyt (LSE:NCYT)
Historical Stock Chart
From May 2023 to May 2024